Andere Sprachen MEI Pharma, Inc. Börse Stuttgart

Aktien

A3D69W

US55279B3015

MMI0

Markt geschlossen - Börse Stuttgart Andere Börsenplätze 16:55:57 14.04.2023			% 5 Tage	% 1. Jan.
4,272 ^EUR	+0,38 %		+1 961,78 %	+1 757,39 %

09.05.	MEI Pharma, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 31. März 2024	CI
11.04.	MEI Pharma, Inc. kündigt strategischen Plan zur Nutzung der jüngsten positiven klinischen Daten von Voruciclib und ME-344 an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14.05.
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	09.05.
MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	09.05.
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	12.04.
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11.04.
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	11.04.
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	11.04.
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11.04.
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	10.04.
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26.03.
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26.03.
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	15.02.
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	13.02.
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13.02.
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	16.01.
MEI Pharma : Change in Certifying Accountants - Form 8-K	26.12.
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14.12.
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	11.12.
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	11.12.
Earnings Flash (MEIP) MEI PHARMA Posts Q1 Revenue $65.3M	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MEI Pharma, Inc. Börse Stuttgart

Aktien

A3D69W

US55279B3015

MMI0

Andere Sprachen

Filter